| __timestamp | CymaBay Therapeutics, Inc. | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 72429000 |
| Thursday, January 1, 2015 | 8871000 | 78634000 |
| Friday, January 1, 2016 | 9645000 | 75374000 |
| Sunday, January 1, 2017 | 12387000 | 92157000 |
| Monday, January 1, 2018 | 14381000 | 93326000 |
| Tuesday, January 1, 2019 | 19238000 | 103132000 |
| Wednesday, January 1, 2020 | 17425000 | 110171000 |
| Friday, January 1, 2021 | 23040000 | 218817000 |
| Saturday, January 1, 2022 | 25116000 | 233827000 |
| Sunday, January 1, 2023 | 51953000 | 267194000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical industry, managing operational costs is crucial. This chart provides a fascinating comparison of Selling, General, and Administrative (SG&A) expenses between Lantheus Holdings, Inc. and CymaBay Therapeutics, Inc. from 2014 to 2023.
Lantheus Holdings, Inc. has consistently outpaced CymaBay Therapeutics, Inc. in SG&A expenses, reflecting its larger scale of operations. In 2023, Lantheus's expenses were approximately 5 times higher than CymaBay's, highlighting its expansive market reach and operational complexity. Over the decade, Lantheus's SG&A expenses grew by 270%, while CymaBay's increased by 535%, indicating a rapid expansion phase for the latter.
This data underscores the strategic financial management required in the pharmaceutical sector, where balancing growth and operational efficiency is key to sustaining competitive advantage.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs CymaBay Therapeutics, Inc.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Insmed Incorporated vs Lantheus Holdings, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Catalent, Inc. and CymaBay Therapeutics, Inc.
Lantheus Holdings, Inc. vs Agios Pharmaceuticals, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs Geron Corporation
SG&A Efficiency Analysis: Comparing Lantheus Holdings, Inc. and MiMedx Group, Inc.
Breaking Down SG&A Expenses: Lantheus Holdings, Inc. vs Evotec SE
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs PTC Therapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: CymaBay Therapeutics, Inc. vs Wave Life Sciences Ltd.
SG&A Efficiency Analysis: Comparing CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd.
Comparing SG&A Expenses: CymaBay Therapeutics, Inc. vs Novavax, Inc. Trends and Insights